Warum steigt der Aktienkurs von THE CIGNA GROUP?
Bullen sagen
Share repurchases and asset sales
Analyst expects renewed share repurchases and proceeds from the Evicore sale to materially support adjusted earnings and offset known headwinds.
Specialty pharmacy growth
Analyst highlights that strength in specialty pharmacy and faster adoption of biosimilars and specialty generics should drive revenue growth and help offset pressures in other segments.
Expense reductions and margin improvement
Analyst notes that reduced investments and lower stranded operating expenses from exiting certain insurance exchange businesses should improve margins and support an earnings recovery.
GLP-1 coverage limitations
Analyst warns that employer decisions to limit coverage of GLP-1 therapies could materially reduce pharmacy benefit revenue and pressure overall growth.
PBM transition uncertainty and costs
Analyst cautions that uncertainty around the transition to a rebate-free PBM model, combined with elevated investment and technology costs, could weigh on earnings and investor sentiment.
Regulatory and margin pressure on PBMs
Analyst flags that increased transparency initiatives and new state laws targeting pharmacy benefit managers may cap PBM profit margins and constrain earnings expansion.
